Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of AZD9668 in Symptomatic COPD
NCT01023516Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Nov 2009
- Primary completion
- Aug 2010
- Modality
- Small Molecules
- Countries
- 6
01
Overview
Phase 2, randomised, double-blind trial in chronic obstructive pulmonary disease (COPD) comparing AZD9668 with Placebo (2 arms). Primary endpoints: Baseline Pre-bronchodilator Forced Expiratory Volume in 1 Second at Day 1 and End-value Pre-bronchodilator Forced Expiratory Volume in 1 Second at 12 weeks. Started Nov 2009; status: completed.
02
Drugs
alvelestat
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT01023516.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01023516.